Arc 12Sanqing’s Global Expansion
Wei Kang expanded Three Purities’ influence through charity, safer cardiovascular drugs, gene-editing technology, and acquisitions of abandoned drug formulas. After building a collection of more than two thousand formulas, he used the system’s drawing function and won a silver prize containing an electronic-product blueprint.
- Taji exposed a Nairobi charity clinic that distributed expired medicines, and the resulting scandal boosted Three Purities as Kenyan authorities shut clinics and turned toward Chinese medical aid.
- Wei Kang established an overseas foundation, appointed Sheng Changya and Zhang Chunming to lead its work, and launched Three Purities’ new cardiovascular drugs.
- Old Man Liang switched from Irbesartan to Sanqing’s antihypertensive drug, while patients and netizens challenged Sanofi’s refusal to recall contaminated medicine in China.
- Director Li ordered Sanofi to recall affected Irbesartan batches, apologize, and compensate patients after tests found nitrosamines, and Three Purities’ drug filled the market gap.
- Sanqing reported more than $40 billion in annual revenue, rewarded its employees, entered Fortune’s Global 500, and Wei Kang became known as the Medicine King.
- Wei Kang announced licensing terms for Sanqing’s fourth-generation gene-editing technology, and Pfizer’s Dr. Duke used samples to make major progress on Hemophilia A research.
- Wei Kang acquired abandoned drug formulas from Pfizer and other pharmaceutical companies after rejecting Weicai’s demand for a share of future projects, then reached a preliminary licensing deal with Takeda Kazuhisa involving roughly five hundred formulas.
- After asking Anmei to sort more than two thousand abandoned prescriptions, Wei Kang spent nearly a hundred thousand points on system draws and won a silver prize containing an electronic-product blueprint.